LINC00645: A Drug Target / Disease Biomarker (G100505967)

Target Name: LINC00645

NCBI ID: G100505967

LINC00645

Other Name(s): Long intergenic non-protein coding RNA 645 | long intergenic non-protein coding RNA 645

LINC00645: A Drug Target / Disease Biomarker

LINC00645 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LINC family of proteins, which are known for their role in regulating gene expression and cell-signaling pathways. LINC00645 has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of LINC00645 is its ability to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in a wide range of cellular processes, including cell survival, growth, and differentiation, and is a key target for many diseases. LINC00645 has been shown to play a role in regulating the PI3K/Akt signaling pathway in various cell types, including cancer cells and neurons.

In addition to its role in cell signaling, LINC00645 is also involved in the regulation of cellular processes that are important for tissue repair and regeneration. It has been shown to play a role in the regulation of cell proliferation, apoptosis, and survival, which are all important for the process of tissue repair and regeneration.

LINC00645 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of neurodegenerative diseases. This includes the regulation of neurotransmitter release, the maintenance of cellular memory and learning, and the regulation of synaptic plasticity.

In addition to its potential role as a drug target or biomarker, LINC00645 is also of interest to researchers as a potential therapeutic agent. Studies have shown that LINC00645 can be inhibited using small molecules, which suggests that it may be a potential drug candidate for the treatment of various diseases. For example, LINC00645 has been shown to be involved in the regulation of neurotransmitter release and has been shown to play a role in the development of neurodegenerative diseases. This suggests that LINC00645 may be an effective therapeutic agent for the treatment of conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Overall, LINC00645 is a protein that has potential as a drug target or biomarker for a variety of diseases. Its ability to interact with multiple signaling pathways and its role in the regulation of cellular processes that are important for tissue repair and regeneration make it an attractive candidate for further research. Further studies are needed to fully understand the role of LINC00645 in disease and to develop safe and effective therapeutic agents that can target this protein.

Protein Name: Long Intergenic Non-protein Coding RNA 645

The "LINC00645 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00645 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets